2,4-Difluoro-1,5-dimethoxy-3-methylbenzene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-Difluoro-1,5-dimethoxy-3-methylbenzene
• 英文别名: 2,4-difluoro-1,5-dimethoxy-3-methylbenzene
• 化学式: C₉H₁₀F₂O₂
• 分子量: 188.17
• InChiKey: DTMLWSSAQLLJSU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
  申请人：CELGENE AVILOMICS RES INC

  公开号：WO2014144737A1

  公开（公告）日：2014-09-18

  The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

  本发明涉及作为蛋白激酶抑制剂的化合物，这些化合物在ATP结合位点包含一个半胱氨酸残基。该发明还提供了包含一种或多种蛋白激酶抑制剂化合物的药用可接受组合物，以及使用所述组合物治疗癌症和癌的方法。
• [EN] 2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES<br/>[FR] COMPOSÉS DE 2-PYRIDAZIN-3(2H)-ONE À SUBSTITUTION 2-ARYLE ET 2-HÉTÉROARYLE UTILISÉS EN TANT QU'INHIBITEURS DE FGFR TYROSINE KINASES
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2017070708A1

  公开（公告）日：2017-04-27

  Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

  本文提供了一般式I的化合物及其立体异构体和药学上可接受的盐或溶剂，其中X、R1、R2、R3、环A和z的含义如规范中所述，这些化合物是FGFR1、FGFR2、FGFR3和/或FGFR4的抑制剂，可用于治疗和预防可以用FGFR抑制剂治疗的疾病，包括由FGFR1、FGFR2、FGFR3和/或FGFR4介导的疾病或障碍。
• HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
  申请人：Incyte Corporation

  公开号：US20170320875A1

  公开（公告）日：2017-11-09

  Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

  揭示了公式（I）的化合物，使用这些化合物作为免疫调节剂的方法，以及包含这些化合物的药物组合物。这些化合物可用于治疗、预防或改善癌症或感染等疾病或疾病。
• [EN] BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICALCOMPOSITIONS AND USES THEREOF<br/>[FR] ACIDES BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIQUES, COMPOSITIONS PHARMACEUTIQUES ET UTILISATIONS ASSOCIÉES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2018138027A1

  公开（公告）日：2018-08-02

  The present invention relates to compounds of general formula (I), wherein the groups R, R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

  本发明涉及一般式（I）的化合物，其中R，R1，R2，R3，m和n组团如权利要求书1中所定义，具有有价值的药理学特性，特别是与GPR40受体结合并调节其活性。这些化合物适用于治疗和预防可以受该受体影响的疾病，如代谢性疾病，特别是2型糖尿病。
• CLASS OF AMINO-SUBSTITUTED NITROGEN-CONTAINING FUSED RING COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF
  申请人：Rudong Ringene Pharmaceuticals, Co. Ltd

  公开号：EP3705480A1

  公开（公告）日：2020-09-09

  The present invention discloses a class of amino-substituted nitrogen-containing fused ring compounds, a preparation method therefor, and a use thereof. The structure of the amino-substituted nitrogen-containing fused ring compounds of the present invention is as shown in formula (I) below, and each group therein is as defined in the specification. The amino-substituted nitrogen-containing fused ring compounds of the present invention are novel specific FGFR kinase inhibitors, having excellent inhibitory activity for FGFR-related tumor cell proliferation, and is applicable to the treatment of diseases such as tumors associated with FGFR kinase mutations or abnormal expressions.

  本发明公开了一类氨基取代的含氮融合环化合物、其制备方法及其用途。本发明的氨基取代的含氮融合环化合物的结构如下式（I）所示，其中各基团如说明书中所定义。本发明的氨基取代的含氮融合环化合物是新型特异性FGFR激酶抑制剂，对FGFR相关肿瘤细胞增殖具有良好的抑制活性，适用于治疗与FGFR激酶突变或异常表达相关的肿瘤等疾病。